



Cerenis Therapeutics acquires Lypro Biosciences

November 9, 2017

San Francisco, CA – Cerenis Therapeutics an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, has acquired the Lypro Biosciences assets including its proprietary drug delivery nanotechnology. The acquisition positions Cerenis at the forefront of the chemotherapy drug delivery and immuno-oncology space.

Jean-Louis Dasseux, CEO of Cerenis Therapeutics, commented: *“We are thrilled to add the Lypro technology development program and nanotechnology platform to our portfolio of world-class HDL assets. Building on the strong foundation of our lead HDL product, CER-001, this acquisition opens another therapeutic area characterized by a significant unmet medical need, while allowing us to leverage our leading HDL therapy capabilities to drive the development of this potentially revolutionary technology.”*

Robert O. Ryan, Ph.D., Founder and Board Member of Lypro, added: *“We are extremely proud of the accomplishments achieved by the Lypro team. The product candidates that Lypro has developed and associated with Cerenis’ proprietary HDL technology could have a tremendous impact on the field of oncology. We believe Cerenis Therapeutics is the optimal company to lead future advancements of this groundbreaking technology. Cerenis Therapeutics holds the appropriate scientific, manufacturing, patent exclusivity, and clinical expertise to continue development of nanotechnology based delivery systems for therapies from laboratory bench to bedside.”*

Michelle Stecklein Call, CEO of Lypro Biosciences, added: *“This agreement marks a transformational step for Lypro Biosciences’ targeted HDL nanotechnology. Cerenis’ lead, drive and focus on HDL is a major competitive advantage to successfully take forward HDL-based targeted nanodelivery technologies to the market.”*

Financial terms of the Lypro Biosciences assets acquisition by Cerenis Therapeutics are not disclosed.

About Lypro Biosciences

Lypro Biosciences, Inc. is privately-held, nanotechnology company, located in the San Francisco Bay Area. Lypro’s proprietary nanotechnology drug delivery platform, NanoDisk, has applications across numerous disease indications. Its product pipeline includes therapies for cancer and infectious disease, amongst others.

Contact:

Michelle S. Call
President and CEO
Lypro Biosciences, Inc.
info@lyprobio.com
www.lyprobio.com